Cancer Research UK

Two major clinical trials presented at ASTRO 2025 reached opposite conclusions about proton beam therapy's effectiveness compared to intensity-modulated radiotherapy (IMRT) for head and neck cancer treatment.

Microbiotica has completed recruitment of 41 patients across four European countries for its MELODY-1 Phase 1b trial evaluating MB097, a precision microbiome therapy combined with pembrolizumab in advanced melanoma patients who failed anti-PD-1 therapy.

Nxera Pharma and Cancer Research UK have dosed the first patient in a Phase 2a trial of HTL0039732, an oral EP4 antagonist immunotherapy for advanced solid tumors.

The IoN trial demonstrated that patients with low-risk differentiated thyroid cancer can safely avoid postoperative radioiodine ablation following thyroidectomy without compromising survival outcomes.

The STAMPEDE trial found that adding metformin to standard care for 1,874 non-diabetic men with metastatic prostate cancer did not significantly improve overall survival (HR 0.91, 95% CI: 0.80-1.03, P = 0.15).

Faron-supported research published in Theranostics identified secreted Clever-1 (sClever-1) as a key immunosuppressive mediator that impairs T-cell responses and contributes to anti-PD-1 therapy resistance in cancer patients.

Swedish researchers found that patients with specific genetic mutations who took 160mg aspirin daily after colorectal cancer surgery were 55% less likely to experience cancer recurrence over three years.

Researchers at The Institute of Cancer Research, London, have demonstrated that combining tazemetostat with DOT1L inhibitor pinometostat can overcome treatment resistance in B-cell lymphoma patients.

The NHS will be the first health system in Europe to trial histotripsy, a non-invasive ultrasound technology that destroys liver tumors using sound waves to create "bubble clouds" that pulverize cancer cells.

The BRAID trial found that contrast-enhanced mammography and abbreviated MRI could detect up to 3,500 additional breast cancers annually in women with dense breasts.